Plain-English translation of NCT03888950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Melanoma is a serious skin cancer that can spread throughout the body. This trial is testing whether a special type of imaging scan, called PET-CT, taken early during treatment with anti-PD-1 immunotherapy (such as nivolumab or pembrolizumab) can help doctors predict whether the medication will work for you. Right now, doctors have no way to know early on whether this treatment will be effective.
About 6 out of 10 patients with advanced melanoma don't respond to this medication, but there are currently no reliable tests to predict who will benefit before starting treatment. If doctors could identify early whether the medication is working, they could switch to a different approach faster for patients who aren't responding, potentially saving time and improving outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive your prescribed anti-PD-1 immunotherapy as planned. You'll have three PET-CT imaging scans: one before starting treatment, one after 2 cycles of medication (roughly 6 weeks in), and one at the 3-month mark. These scans use a special imaging technique to measure how your tumor is responding at a cellular level. The study involves about 20 patients and takes approximately 3 months.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France